— Know what they know.
Not Investment Advice

ROG NYSE

Rogers Corporation
1W: -7.3% 1M: +9.7% 3M: +23.2% YTD: +44.0% 1Y: +93.2% 3Y: -15.5% 5Y: -28.9%
$135.13
+2.73 (+2.06%)
 
Weekly Expected Move ±6.0%
$123 $131 $140 $148 $157
NYSE · Technology · Hardware, Equipment & Parts · Alpha Radar Neutral · Power 56 · $2.4B mcap · 18M float · 1.25% daily turnover · Short 33% of daily vol
0.00
Neutral
0 bullish 0 neutral 0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish 0 neutral 0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (63)
Rogers Corp. (ROG) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Bullish Zacks · 1d ago · 0.90
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Bullish GlobeNewsWire-CompanyAnnouncements · 4d ago · 0.90
Is Rogers Corporation (ROG) A Good Stock To Buy Now?
Yahoo-TopStories · 1w ago · 0.00
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Bullish GlobeNewsWire-CompanyAnnouncements · 1w ago · 0.90
Rogers Corp. SVP Sells 830 Shares Worth $113,000 as the Stock Continues Its Climb. Time to Sell?
Bearish MotleyFool · 2w ago · -0.90
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Bullish GlobeNewsWire-CompanyAnnouncements · 2w ago · 0.90
Rogers Corp. (ROG) is a Great Momentum Stock: Should You Buy?
Bullish Zacks · 3w ago · 0.90
Meta, Ford, Willis Towers Watson And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Bearish Benzinga-News · 3w ago · -0.90
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
Bullish GlobeNewsWire-CompanyAnnouncements · 3w ago · 0.90
Rogers Corporation Q1 2026 Earnings Call Summary
Yahoo-Earnings · 3w ago · 0.00
Rogers (ROG) Q1 2026 Earnings Call Transcript
MotleyFool · 3w ago · 0.00
Rogers forecasts Q2 adjusted EPS of $0.90 to $1.10 with adjusted EBITDA margin at 17.7% midpoint
Bullish SeekingAlpha · 3w ago · 0.90
Rogers Corp. (ROG) Q1 Earnings Beat Estimates
Bullish Zacks · 3w ago · 0.90
Rogers Q1 2026 Earnings Call: Complete Transcript
Benzinga-News · 3w ago · 0.00
Rogers Corporation (NYSE: ROG) lifts Q1 2026 margins and posts quarterly profit - Stock Titan
Bullish Google-Earnings · 3w ago · 0.90
Rogers Non-GAAP EPS of $0.75 beats by $0.07, revenue of $200.5M in-line
Bullish SeekingAlpha · 3w ago · 0.90
Rogers (ROG) Q2 2025 Earnings Call Transcript
MotleyFool · 3w ago · 0.00
Here are the major earnings after the close Tuesday
SeekingAlpha · 3w ago · 0.00
Earnings Scheduled For April 28, 2026
Bearish Benzinga-Earnings · 3w ago · -0.90
Rogers (NYSE:ROG) Shares Gap Up – Should You Buy?
Bullish DefenseWorld · 3w ago · 0.90
Rogers Corp. (ROG) Soars 6.4%: Is Further Upside Left in the Stock?
Bearish Zacks · 4w ago · -0.90
Texas Instruments jumps as data center revenue surges 90%; leads analog stocks higher
Bullish SeekingAlpha · 4w ago · 0.90
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
GlobeNewsWire-CompanyAnnouncements · 4w ago · 0.00
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens
GlobeNewsWire-CompanyAnnouncements · 4w ago · 0.00
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
GlobeNewsWire-CompanyAnnouncements · 4w ago · 0.00
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
GlobeNewsWire-CompanyAnnouncements · 4w ago · 0.00
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
GlobeNewsWire-CompanyAnnouncements · 4w ago · 0.00
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
GlobeNewsWire-CompanyAnnouncements · 5w ago · 0.00
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
Bullish GlobeNewsWire-CompanyAnnouncements · 7w ago · 0.90
Rogers (NYSE:ROG) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
Bullish DefenseWorld · 8w ago · 0.90
Roche eröffnet neues Forschungsgebäude für das Institute of Human Biology und leistet damit Pionierarbeit im Bereich menschlicher Modellsysteme, um Entwicklung von Medikamenten zu beschleunigen
Bullish GlobeNewsWire-CompanyAnnouncements · 8w ago · 0.90
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
Bullish GlobeNewsWire-CompanyAnnouncements · 8w ago · 0.90
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
Bullish GlobeNewsWire-CompanyAnnouncements · 9w ago · 0.90
Cinctive Capital Management LP Invests $5.34 Million in Rogers Corporation $ROG
Bullish DefenseWorld · 9w ago · 0.90
Roche Annual General Meeting 2026
Bullish GlobeNewsWire-CompanyAnnouncements · 10w ago · 0.90
Assemblée générale annuelle 2026 de Roche
Bullish GlobeNewsWire-CompanyAnnouncements · 10w ago · 0.90
Roche Generalversammlung 2026
Bullish GlobeNewsWire-CompanyAnnouncements · 10w ago · 0.90
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
GlobeNewsWire-CompanyAnnouncements · 10w ago · 0.00
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Bullish GlobeNewsWire-CompanyAnnouncements · 11w ago · 0.90
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Bullish GlobeNewsWire-CompanyAnnouncements · 11w ago · 0.90
Clearline Capital Increases Core Scientific Stake as Bitcoin Mining Becomes a Data Center Business
Bullish MotleyFool · 11w ago · 0.90
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
Bullish GlobeNewsWire-CompanyAnnouncements · 11w ago · 0.90
Clearline Capital Trims Semtech as Post-Sierra Model Drives Earnings
Bearish MotleyFool · 12w ago · -0.90
Media Mogul Tom Rogers: Netflix has a great path ahead after freeing itself from Warner Bros. deal
Bullish YouTube · 12w ago · 0.90
The Great Canadian Jersey Coming to the Hockey Hall of Fame
GlobeNewsWire · 12w ago · 0.00
Rogers Satellite Transforming IoT Connectivity for Asset and Fleet Management Technology
Bullish GlobeNewsWire · 12w ago · 0.90
Rogers Corporation Reports Fourth Quarter and Full Year 2025 Results
Bullish BusinessWire · 13w ago · 0.90
What Might Be Behind One Fund's New $40 Million Bet on Rogers Corporation Stock?
Bullish MotleyFool · 13w ago · 0.90
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
Bullish GlobeNewsWire · 14w ago · 0.90
Nuance Investments LLC Lowers Position in Rogers Corporation $ROG
Bearish DefenseWorld · 14w ago · -0.90
Rogers Sugar Delivers Strong First Quarter Results, Driven by Focus on Execution in Both Business Segments
Bullish GlobeNewsWire · 15w ago · 0.90
Rogers Sugar Inc. Declares Dividend to Shareholders
Bullish GlobeNewsWire · 15w ago · 0.90
REMINDER - Rogers Sugar Inc.: Conference Call – 1st Quarter 2026 Results
GlobeNewsWire · 15w ago · 0.00
Rogers Corporation Schedules Fourth Quarter 2025 Earnings Call for February 17
BusinessWire · 15w ago · 0.00
Y Intercept Hong Kong Ltd Grows Position in Rogers Corporation $ROG
Bullish DefenseWorld · 15w ago · 0.90
Rogers Sugar: Revisiting The Thesis As LEAP Is Delayed
Bullish SeekingAlpha · 16w ago · 0.90
Rogers Sugar Inc.: Conference Call – 1st Quarter 2026 Results
GlobeNewsWire · 18w ago · 0.00
Rogers (NYSE:ROG) Stock Crosses Above 200 Day Moving Average – Should You Sell?
Bullish DefenseWorld · 19w ago · 0.90
Rogers Corporation $ROG Shares Bought by Geode Capital Management LLC
Bullish DefenseWorld · 25w ago · 0.90
Rogers Sugar Inc. Declares Dividend to Shareholders
Bullish GlobeNewsWire · 25w ago · 0.90
Rogers Sugar Reports Strong Profitability Growth in 2025, Fuelled by our Focus on Servicing our Customers and Disciplined Execution
Bullish GlobeNewsWire · 25w ago · 0.90
REMINDER — Rogers Sugar Inc.: Conference Call – 4th Quarter 2025 Results
GlobeNewsWire · 25w ago · 0.00
Creative Planning Has $2.50 Million Stock Holdings in Rogers Corporation $ROG
Bullish DefenseWorld · 25w ago · 0.90

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms